CIVETAN   23983
CENTRO DE INVESTIGACION VETERINARIA DE TANDIL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Pharmaco-therapeutic evaluation of the closantel-moxidectin combination in lambs.
Autor/es:
SUAREZ, G.; ALVAREZ, L.; CASTELLS, D.; BERRETTA, C.; BENTANCOR, S.; FAGIOLINO, P.; LANUSSE, C.
Lugar:
Perth
Reunión:
Conferencia; 24th International Conference of the World Association for the Advancement of Veterinary Parasitology; 2013
Institución organizadora:
World Association for the Advancement of Veterinary Parasitology
Resumen:
Abstract: The serious widespread development of nematode resistance has motivated the use of combined anthelmintic formulations. However, the advantages/disadvantages of the combined use of anthelmintics require further scientific characterization. The goals of the current trial were: a) to characterize the pharmacokinetics (PK) of CLS and MXD administered orally and subcutaneously either separately or co-administered (CLS+MXD) to lambs; b) to compare the nematodicidal activity of both molecules given separately or co-administered to lambs infected with resistant nematodes. Ninety (90) Corriedale lambs naturally infected with multiple resistant gastrointestinal nematodes were involved on the following trials: a) PK trial: The animals were allocated into six groups and treated with either CLS (10 mg/kg), MXD (0.2 mg/kg) or with the a CLS+MXD combined formulation by both the oral and subcutaneous routes. Blood samples were collected over 28 days post-treatment and drug plasma concentrations measured by HPLC. b) Efficacy trial: An untreated control group (n=10) was included. The efficacy at 13 days post-treatment was estimated by the faecal egg count reduction test (FECRT). A higher systemic exposure measured as plasma AUC) of both CLS and MXD were observed after the parenteral compared to the oral administration of both molecules in lambs. The combined administration of both anthelmintics did not markedly alter their disposition kinetics. The administration of both molecules as a single active principle reached efficacy levels (estimated as the FECRT) ranging from 80% (MXD oral), 84% (CLS oral) up to 85% (CLS sc) and 92% (MXD sc). However, the combined treatments given both orally and subcutaneously reached a 100% efficacy. While the co-administration CLS+MXD did not show any adverse pharmacokinetic interaction, their combined anthelmintic effect was sufficient to restore the maximum efficacy levels, which were not reached by the individual active ingredients. This work is a further contribution to the need of more pharmacological investigation before drug combinations are developed and introduced into the market.